Clinical trials
Phase 1 Endocrine System Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Withdrawn | 3 |
| Recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Pittsburgh | 5 |
| Goldfinch Bio, Inc. | 2 |
| Biohaven Therapeutics Ltd. | 1 |
| Black Tie Medical, Inc. | 1 |
| Corbus Pharmaceuticals Inc. | 1 |
| Corcept Therapeutics | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Hanmi Pharmaceutical Company Limited | 1 |
| Neurocrine Biosciences | 1 |
| Pfizer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Endocrine System Diseases | 16 |
| Metabolic Diseases | 5 |
| Musculoskeletal Diseases | 5 |
| Osteoporosis | 5 |
| Diabetes Mellitus | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Glucose Metabolism Disorders | 3 |
| Hyperparathyroidism | 3 |
| Adrenal Gland Diseases | 2 |
| Adrenocortical Hyperfunction | 2 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.